Dynamin 2 inhibitor for the treatment of centronuclear myopathies
AssigneesUniversite De Strasbourg, Centre National De La Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale
InventorsJocelyn Laporte, Belinda Cowling, Hichem Tasfaout
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.
Claims7
A method for the treatment of a X-linked centronuclear myopathy (XL-CNM) in a subject in need of said treatment, said method comprising administering to said subject in need of said treatment a therapeutically efficient amount of an inhibitor of Dynamin 2, said inhibitor being a RNAi, an antisense nucleic acid, a siRNA, a shRNA or a ribozyme interfering specifically with Dynamin 2 expression.
Dependencies are inferred from the claim text.